Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anavex Life Sciences Corp AVXL

Healthcare Biotechnology
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of... see more

Recent & Breaking News (NDAQ:AVXL)

Anavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and to Reveal New Epilepsy Data at Antiepileptic Drug Trials XIII Conference

GlobeNewswire April 23, 2015

Anavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain Injuries

GlobeNewswire April 7, 2015

Anavex Presents Positive Results for Both ANAVEX 2-73 and ANAVEX 3-71 in Alzheimer's Models at 2015 AD/PD(TM) Conference

GlobeNewswire March 23, 2015

New Data on Two Anavex Alzheimer's Drugs to be Unveiled at AD/PD 2015

GlobeNewswire March 19, 2015

Anavex to Participate in Phase 3 Clinical Trials Panel at AD/PD 2015

GlobeNewswire March 17, 2015

Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory Board

GlobeNewswire March 12, 2015

Anavex to Present at Sigma-1 Receptors Symposium

GlobeNewswire March 10, 2015

Anavex Appoints Scientific Advisory Board Member With Expertise in Protein Misfolding Neurodegenerative Diseases

GlobeNewswire March 5, 2015

Anavex to Present at 27th Annual ROTH Conference on March 11th

GlobeNewswire March 3, 2015

ANAVEX 2-73 Could Prevent Alzheimer's Disease in Addition to Modifying and Treating Symptoms

GlobeNewswire February 25, 2015

Amarantus Announces First Alzheimer's Biomarker Services Collaboration for LymPro Test(R) With Anavex Life Sciences Corp.

GlobeNewswire February 18, 2015

Anavex Reports Fiscal First Quarter 2015 Financial Results

GlobeNewswire February 18, 2015

Anavex Confirms Positive Preclinical Epilepsy Data for ANAVEX 2-73 - Validation as Potential Platform Drug for Multiple Neurodegenerative Diseases

GlobeNewswire February 9, 2015

Anavex to Present at 17th Annual BIO CEO & Investor Conference on February 10th

GlobeNewswire February 4, 2015

Anavex Doses First Alzheimer's Patient in Phase 2a Trial of ANAVEX 2-73 and ANAVEX PLUS

GlobeNewswire January 12, 2015

Anavex Announces Panel Discussion and Presention at OneMedForum Conference

GlobeNewswire January 8, 2015

Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor's Beneficial Direct Interaction With Cannabinoid Receptor

GlobeNewswire January 6, 2015

Anavex Announces Fiscal 2014 Fourth Quarter and Year-End Financial Results

GlobeNewswire December 30, 2014

Anavex to Present at Biotech Showcase 2015 in San Francisco

GlobeNewswire December 18, 2014

Anavex Begins Enrollment of Alzheimer's Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS

GlobeNewswire December 16, 2014